GLP-1 receptor agonist use in adults with concurrent type 2 diabetes and obesity was associated with increased risk for osteoporosis, gout and osteomalacia vs. a matched control group, according to ...

The FDA has approved the first medication for cholestatic pruritus in adult patients with primary biliary cholangitis.The approval of linerixibat (Lynavoy, GSK) — an ileal bile acid transporter ...

Ndemex, a formulation of tea tree oil designed to promote ocular hygiene, is now available.It can be used once daily to help “support good ocular health in the fight against blepharitis and other ...

Epioxa, the first FDA-approved epithelium-on cross-linking procedure, is now commercially available, according to a press release from Glaukos.

The likelihood that a person with early-stage non-small cell lung cancer will receive curative treatment still varies considerably by race, even though 3 decades have passed since researchers first ...

The FDA approved a higher 7.2 mg dose of injectable semaglutide for adults with overweight and obesity, Novo Nordisk announced. Once-weekly injectable semaglutide 7.2 mg (Wegovy HD, Novo Nordisk) ...

Waist circumference, not BMI, was tied to increased risk for adiposity-related heart failure, and the association was ...

For most children with complicated pneumonia, a less aggressive treatment approach is favored for those with small or moderate pleural effusions, according to updated guidance. The Infectious Diseases ...

A GIP/GLP-1/glucagon triple agonist reduced HbA1c by up to 1.9 percentage points at 40 weeks for adults with type 2 diabetes, according to topline results from the TRANSCEND-T2D-1 trial. Retatrutide ...

Tirzepatide provided a larger reduction in HbA1c and greater improvements in multiple cardiometabolic parameters compared with conventional care for adults recently diagnosed with type 2 diabetes, ...

With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease ...

In this video, Paolo Tarantino, MD, PhD, an advanced fellow at Dana-Farber Cancer Institute, discusses the pros and cons of trastuzumab deruxtecan in neoadjuvant and adjuvant settings.Tarantino said a ...